Patient P-02146
Therapy response
Unstable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 74 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 79 GI-04 recommended — GI Support Protocol GI-04
- Day 80 Patient declined — Not now
- Day 93 ME-01 recommended — Monitoring Escalation ME-01
- Day 94 Patient accepted — Started ME-01 in the companion
- Day 97 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 74.
Primary contributors, last 14 days
- Toxicity-11
- GI instability+7
- Nutritional resilience-5
- Inflammatory activity-2
- Treatment adherence-2
What helped?
- GI Support Protocol GI-04Day 79Declined by patient
- Monitoring Escalation ME-01Day 93Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 87% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 34/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑65
- WearableResting HR 88 bpm
- Wearable614 steps/day
- WearableShort sleep window
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 73 and rising
- WearableSleep 5.6 h, below personal baseline
- Inflammatory signalling ↓60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 63
- WearableHRV 16 ms, trending down
- Drug metabolism and exposure ↑20
- BloodToxicity index 48
DNA
Fictional pharmacogenomic panel
- CYP2D6 Rapid metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 2.8 · butyrate capacity 34/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 16 ms
- Sleep
- 5.1 h
- Steps
- 1,750
- Resting HR
- 86 bpm
Daily log: GI score 73, nutritional resilience 30, adherence 42.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02048 | 16% | S02 | — | — | 77 |
| P-02115 | 17% | S14 | GI-04 | improved | 75 |
| P-02575 | 18% | S14 | ME-01 | improved | 73 |
| P-02192 | 16% | S05 | — | — | 69 |
| P-02659 | 18% | S09 | — | — | 69 |
| P-02356 | 16% | S08 | — | — | 69 |
| P-02293 | 16% | S15 | HY-01 | no change | 68 |
| P-02591 | 25% | S13 | — | — | 68 |
| P-02090 | 16% | S04 | — | — | 68 |
| P-02265 | 23% | S07 | GI-04 | no change | 67 |
| P-02530 | 24% | S07 | — | — | 67 |
| P-02194 | 16% | S03 | — | — | 67 |